Robert W. Baird Analysts Give Mersana Therapeutics (MRSN) a $20.00 Price Target  Donna Armstrong | Aug 17th, 2018
Mersana Therapeutics (NASDAQ:MRSN) has been assigned a $20.00 price target by research analysts at Robert W. Baird in a research note issued on Wednesday. The brokerage presently has a "buy" rating on the stock. Robert W. Baird's target price suggests a potential upside of 58.86% from the company's previous close.
Other analysts have also recently issued reports about the company. HC Wainwright set a $33.00 price target on Mersana Therapeutics and gave the company a "buy" rating in a research report on Tuesday, April 17th. ValuEngine upgraded Mersana Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 29th. Finally, Zacks Investment Research upgraded Mersana Therapeutics from a "hold" rating to a "buy" rating and set a $18.00 price target on the stock in a research report on Wednesday, June 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Mersana Therapeutics has a consensus rating of "Hold" and an average price target of $27.60. Get Mersana Therapeutics alerts:
Shares of NASDAQ:MRSN opened at $12.59 on Wednesday. Mersana Therapeutics has a fifty-two week low of $8.76 and a fifty-two week high of $23.96. The firm has a market capitalization of $294.75 million, a price-to-earnings ratio of -3.91 and a beta of -2.34.
Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings results on Wednesday, August 15th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. The firm had revenue of $4.19 million for the quarter, compared to analysts' expectations of $3.74 million. equities research analysts anticipate that Mersana Therapeutics will post -2.37 EPS for the current fiscal year.
In other news, insider Timothy B. Lowinger sold 3,500 shares of the stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $11.06, for a total transaction of $38,710.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink . 39.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the company. American International Group Inc. grew its holdings in shares of Mersana Therapeutics by 110.1% during the first quarter. American International Group Inc. now owns 7,151 shares of the company's stock worth $113,000 after purchasing an additional 3,747 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Mersana Therapeutics by 20.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 24,500 shares of the company's stock worth $438,000 after purchasing an additional 4,200 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 10.1% during the fourth quarter. Geode Capital Management LLC now owns 63,173 shares of the company's stock worth $1,037,000 after purchasing an additional 5,821 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Mersana Therapeutics by 27.4% during the second quarter. Bank of New York Mellon Corp now owns 31,615 shares of the company's stock worth $564,000 after purchasing an additional 6,804 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Mersana Therapeutics by 1,132.7% during the fourth quarter. TIAA CREF Investment Management LLC now owns 8,037 shares of the company's stock worth $132,000 after purchasing an additional 7,385 shares during the last quarter. Institutional investors own 81.75% of the company's stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Mersana Therapeutics Mersana Therapeutic